BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), the BeOne Care Foundation, and The Max Foundation have renewed a partnership through 2028 to provide access to the cancer drug BRUKINSA® (zanubrutinib) for patients with chronic lymphocytic leukemia (CLL) in low- and middle-income countries.

The renewed agreement aims to support approximately 1,000 patients cumulatively by 2028. The original collaboration, launched in 2023, has so far provided access to BRUKINSA for more than 300 patients across Armenia, Ethiopia, and Nepal, exceeding the program's initial scope by roughly 150 patients.

Under the renewed terms, the partnership will continue operating in those three countries while potentially expanding into Côte d'Ivoire, Malawi, Mongolia, Mozambique, Togo, and Zambia, subject to operational readiness. The collaboration includes donated BRUKINSA from BeOne Medicines and a $1 million grant from the BeOne Care Foundation to cover patient care, physician engagement, and operational costs over the next two years. Patients enrolled in the program will continue receiving treatment beyond the partnership term for as long as it is medically needed.

CLL is estimated to account for about one-third of new leukemia cases in adults, with approximately 191,000 new diagnoses recorded worldwide each year, according to published research cited in the press release.

"Renewing this partnership with The Max Foundation reflects both the impact we have already achieved together and our commitment to reaching many more patients who otherwise may have limited treatment options," said John V. Oyler, Co-Founder, Chairman, and CEO of BeOne Medicines.

Pat Garcia-Gonzalez, Co-Founder and CEO of The Max Foundation, said the organizations have helped hundreds of patients access treatment and welcomed the expansion to more countries and patients.